Michael Milsom – Stress-induced stem cell attrition as a driver of hematologic ageing

Max Planck Seminar

  • Datum: 16.03.2017
  • Uhrzeit: 16:00 c.t. - 17:00
  • Vortragende(r): Michael Milsom
  • Heidelberg Institute for stem cell technology and Experimental Medicine (HI-STEM), Heidelberg, Germany
  • Ort: MPI-IE
  • Raum: Main Lecture Hall
  • Gastgeber: Eirini Trompouki
Michael Milsom – Stress-induced stem cell attrition as a driver of hematologic ageing
Michael Milsom, group leader of the HI-STEM Experimental Hematology Group in Heidelberg will visit the MPI-IE on March 16th, 2017. He will give his talk at 4pm in the Main Lecture Hall of the institute. The talk is entitled “Stress-induced stem cell attrition as a driver of hematologic ageing.”

Research

“The Experimental Hematology group of Michael Milsom is broadly interested in understanding fundamental biological properties of adult stem cells and applying this knowledge to gain new insight into human diseases and in the development of novel therapeutic strategies that may eventually be translated into the clinic to treat such diseases. The group is primarily concerned with the study of the adult mammalian blood system and the hematopoietic stem cells (HSCs) that are responsible for maintaining the lifelong production of mature blood cells. The work of the group predominantly revolves around using the experimental mouse model of hematopoiesis, since the blood system in mice closely mimics many key features of human hematopoiesis. However, the group is also increasing concerned with using material from normal human donors as well as patient populations with specific disease entities, in order to validate that key findings obtained using the mouse model can also be recapitulated in human blood-forming cells. Finally, a sub-focus of the group is the use of pluripotent stem cell lines, such as murine embryonic stem (ES) cells or human induced pluripotent stem cells (iPSCs), which can act as an expandable source of cells that can be directed towards differentiating into hematopoietic stem and progenitor cells.”


CV

Michael Milsom obtained his PhD in Biochemistry and Molecular Biology at the University of Leeds, UK in 2000. As a Post-Doc he worked in the lab of Dr Leslie Fairbairn at the Paterson Institute for Cancer Research in Manchester and afterwards in the group of Dr. David A. Williams at Cincinnati Children’s Hospital Medical Center, USA. In 2007 he became Associate Research Scientist Division of Hematology/Oncology, Children’s Hospital Boston, Boston, USA. Since September 2010 Michael Milson is junior group leader at the Heidelberg Institute for stem cell technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.
source: HI-STEM
Zur Redakteursansicht